Revolution Medicines Announces Planned Retirement of President and Key Executive Changes

Details

announced that Dr. Steve Kelsey, its President of Research and Development, intends to retire effective January 4, 2027. Dr. Kelsey will transition to a new role as Senior Advisor to the CEO starting July 1, 2026. The company also held its annual meeting of stockholders on the same day, where two new Class III directors were elected, the appointment of PricewaterhouseCoopers LLP as the independent auditor was ratified, and the compensation of named executive officers was approved on an advisory basis.

Items reported

About Revolution Medicines Inc.

Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.